成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. 誘導(dǎo)疾病模型產(chǎn)品 Stem Cell/Wnt Metabolic Enzyme/Protease Vitamin D Related/Nuclear Receptor Cell Cycle/DNA Damage Autophagy
  3. 免疫與炎癥疾病模型 Organoid RAR/RXR PPAR Endogenous Metabolite Autophagy
  4. 半抗原
  5. Retinoic acid

Retinoic acid  (Synonyms: 維生素A酸; Vitamin A acid; all-trans-Retinoic acid; ATRA)

目錄號: HY-14649 純度: 99.81%
COA 產(chǎn)品使用指南

Retinoic acid 是維生素 A 的代謝產(chǎn)物，在細(xì)胞生長，分化和器官發(fā)生中起重要作用。Retinoic acid 是 RAR 核受體的天然激動劑，對 RARα/β/γ的 IC50 為14 nM。 Retinoic acid與 PPARβ/δ 結(jié)合的 Kd 值為 17 nM。Retinoic acid 可以通過激活視黃酸受體抑制轉(zhuǎn)錄因子 Nrf2。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Retinoic acid Chemical Structure

Retinoic acid Chemical Structure

CAS No. : 302-79-4

1.  客戶無需承擔(dān)相應(yīng)的運輸費用。

2.  同一機構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機構(gòu)（單位）一年內(nèi)

     可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥550
In-stock
100 mg ￥500
In-stock
500 mg ￥750
In-stock
1 g ￥1014
In-stock
5 g   詢價  
10 g   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of Retinoic acid:

MCE 顧客使用本產(chǎn)品發(fā)表的 62 篇科研文獻

WB

    Retinoic acid purchased from MCE. Usage Cited in: Oncotarget. 2017 Nov 22;8(65):109135-109150.  [Abstract]

    MCF-7 cells are pretreated with the indicated chemical inhibitors for 30min, followed by 15 min treatment with RA (20 μM) + EPA (80 μM).Cell extracts are prepared and subjected to western blotting analysis.

    Retinoic acid purchased from MCE. Usage Cited in: Oncotarget. 2017 Nov 22;8(65):109135-109150.  [Abstract]

    Cells are treated with RA (20 μM) plus ω-3 PUFAs (80 μM) with or without CQ (5 μM) for 24 h. Cell extracts are prepared and subjected to western blotting analysis.

    Retinoic acid purchased from MCE. Usage Cited in: Oncotarget. 2017 Nov 22;8(65):109135-109150.  [Abstract]

    Cell morphology of MCF-7 treated with RA (20 μM)+ω-3 PUFAs (80 μM) with or without 3-MA (5 mM) for 24h.

    查看 RAR/RXR 亞型特異性產(chǎn)品:

    查看 PPAR 亞型特異性產(chǎn)品:

    • 生物活性

    • 實驗參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻

    生物活性

    Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.

    IC50 & Target[2][5]

    PPARβ/δ

    17 nM (Kd)

    PPARα

    103 nM (Kd)

    PPARγ

    178 nM (Kd)

    Human Endogenous Metabolite

     

    PPARα

    14 nM (IC50)

    PPARγ

    14 nM (IC50)

    RARβ

    14 nM (IC50)

    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    3LLD122 IC50
    33 μM
    Compound: ATRA
    Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%
    Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%
    		[PMID: 10956204]
    COLO 205 IC50
    37 μM
    Compound: ATRA
    Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay
    Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay
    		[PMID: 20405849]
    COS-7 EC50
    0.2 nM
    Compound: ATRA
    Activity at human RARgamma ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay
    Activity at human RARgamma ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay
    		[PMID: 19058965]
    COS-7 EC50
    0.6 nM
    Compound: ATRA
    Transactivation of GAL4-fused mouse RARgamma-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay
    Transactivation of GAL4-fused mouse RARgamma-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay
    		[PMID: 30792038]
    COS-7 EC50
    1.2 nM
    Compound: ATRA
    Transactivation of GAL4-fused mouse RARalpha-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay
    Transactivation of GAL4-fused mouse RARalpha-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay
    		[PMID: 30792038]
    COS-7 EC50
    1.2 nM
    Compound: ATRA
    Transactivation of GAL4-fused mouse RARbeta-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay
    Transactivation of GAL4-fused mouse RARbeta-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay
    		[PMID: 30792038]
    COS-7 EC50
    12 nM
    Compound: ATRA
    Activity at human RARbeta ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay
    Activity at human RARbeta ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay
    		[PMID: 19058965]
    COS-7 EC50
    17 nM
    Compound: ATRA
    Activity at human RARalpha ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay
    Activity at human RARalpha ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay
    		[PMID: 19058965]
    CV-1 EC50
    0.7 nM
    Compound: RA
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor gamma using transactivation assay
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor gamma using transactivation assay
    		10.1016/0960-894X(95)00588-K
    CV-1 EC50
    1 nM
    Compound: RA
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor beta using transactivation assay
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor beta using transactivation assay
    		10.1016/0960-894X(95)00588-K
    CV-1 EC50
    1100 nM
    Compound: RA
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor gamma using transactivation assay
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor gamma using transactivation assay
    		10.1016/0960-894X(95)00588-K
    CV-1 EC50
    1400 nM
    Compound: RA
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor beta using transactivation assay
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor beta using transactivation assay
    		10.1016/0960-894X(95)00588-K
    CV-1 EC50
    7 nM
    Compound: RA
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor alpha using transactivation assay
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor alpha using transactivation assay
    		10.1016/0960-894X(95)00588-K
    CV-1 EC50
    900 nM
    Compound: RA
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor alpha using transactivation assay
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor alpha using transactivation assay
    		10.1016/0960-894X(95)00588-K
    CWR22R GI50
    25.11 μM
    Compound: 1, ATRA
    Growth inhibition of human CWR22Rv1 cells by MTT assay
    Growth inhibition of human CWR22Rv1 cells by MTT assay
    		[PMID: 25634130]
    DU-145 GI50
    11.64 μM
    Compound: ATRA, Tretinoin
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 25701251]
    F9 IC50
    0.1 nM
    Compound: 7, trans- RA
    Induction of terminal differentiation in mouse F9 cells assessed by measuring secreted plasminogen activator activity after 3 days
    Induction of terminal differentiation in mouse F9 cells assessed by measuring secreted plasminogen activator activity after 3 days
    		[PMID: 17489579]
    F9 ED50
    0.1 nM
    Compound: 1
    Ability to displace 3 uM retinoid and [3H]all-trans-retinoic acid in F9 embryonal carcinoma cells using F9 Plasminogen Activator releasing assay
    Ability to displace 3 uM retinoid and [3H]all-trans-retinoic acid in F9 embryonal carcinoma cells using F9 Plasminogen Activator releasing assay
    		[PMID: 2738885]
    Fibroblast IC50
    10 μM
    Compound: retinoic acid
    Inhibition of UVB irradiation-induced MMP1 production in human dermal fibroblasts after 48 hrs
    Inhibition of UVB irradiation-induced MMP1 production in human dermal fibroblasts after 48 hrs
    		[PMID: 18029185]
    HEK-293T IC50
    28.7 μM
    Compound: Retinoic acid
    Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis
    Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis
    		[PMID: 23122865]
    HEK-293T IC50
    301.3 μM
    Compound: Retinoic acid
    Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis
    Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis
    		[PMID: 23122865]
    HL-60 ED50
    2.4 nM
    Compound: retinoic acid
    The ability to induce differentiation of human promyelocytic leukemia cell line HL-60 to mature granulocytes was determined by nitro blue tetrazolium (NBT) reduction assay
    The ability to induce differentiation of human promyelocytic leukemia cell line HL-60 to mature granulocytes was determined by nitro blue tetrazolium (NBT) reduction assay
    		[PMID: 8182710]
    HL-60 ED50
    2.4 nM
    Compound: RA
    Differentiation inducing activity towards human promyelocytic leukemia cell line HL-60 assayed by nitroblue tetrazolium reduction
    Differentiation inducing activity towards human promyelocytic leukemia cell line HL-60 assayed by nitroblue tetrazolium reduction
    		[PMID: 2704028]
    HL-60 CC50
    23 nM
    Compound: ATRA; RA
    Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 72 hrs by trypan blue staining based assay
    Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 72 hrs by trypan blue staining based assay
    		[PMID: 33895500]
    HL-60 ED50
    50 nM
    Compound: 1
    Compound was evaluated for the retinoid-induced differentiation of the human myeloid leukemia cell line HL-60 using trans-retinoic acid as the standard.
    Compound was evaluated for the retinoid-induced differentiation of the human myeloid leukemia cell line HL-60 using trans-retinoic acid as the standard.
    		[PMID: 1992144]
    HT-29 CC50
    4.3 μM
    Compound: ATRA; RA
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 33895500]
    HT-29 IC50
    4.3 μM
    Compound: ATRA
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 20405849]
    LNCaP IC50
    10 μM
    Compound: 1
    Growth inhibition of human LNCaP cells after 6 days by MTT assay
    Growth inhibition of human LNCaP cells after 6 days by MTT assay
    		[PMID: 15615521]
    LNCaP GI50
    10.33 μM
    Compound: ATRA, Tretinoin
    Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 25701251]
    LNCaP GI50
    47.86 μM
    Compound: 1, ATRA
    Growth inhibition of human LNCAP cells by MTT assay
    Growth inhibition of human LNCAP cells by MTT assay
    		[PMID: 25634130]
    LNCaP IC50
    5 x 10-1 μM
    Compound: ATRA
    Antiproliferative activity against human LNCAP cells after 48 hrs by MTT assay
    Antiproliferative activity against human LNCAP cells after 48 hrs by MTT assay
    		[PMID: 19375825]
    MCF7 IC50
    0.58 μM
    Compound: 1
    Growth inhibition of human MCF7 cells after 6 days by MTT assay
    Growth inhibition of human MCF7 cells after 6 days by MTT assay
    		[PMID: 15615521]
    MCF7 GI50
    12.39 μM
    Compound: ATRA, Tretinoin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 25701251]
    MCF7 CC50
    20 nM
    Compound: ATRA; RA
    Antiproliferative activity in human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by cell counting assay
    Antiproliferative activity in human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by cell counting assay
    		[PMID: 33895500]
    MCF7 IC50
    6.14 μM
    Compound: atRA
    Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs
    Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs
    		[PMID: 33139111]
    MDA-MB-231 GI50
    10.85 μM
    Compound: ATRA
    Growth inhibition of human MDA-MB-231 cells after 5 days by MTT assay
    Growth inhibition of human MDA-MB-231 cells after 5 days by MTT assay
    		[PMID: 18543902]
    MDA-MB-231 GI50
    14.12 μM
    Compound: 1, ATRA
    Growth inhibition of human MDA-MB-231 cells by MTT assay
    Growth inhibition of human MDA-MB-231 cells by MTT assay
    		[PMID: 25634130]
    MDA-MB-231 IC50
    16 μM
    Compound: atRA
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    		[PMID: 33139111]
    MDA-MB-453 GI50
    9.51 μM
    Compound: ATRA, Tretinoin
    Cytotoxicity against human MDA-MB-453 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-453 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 25701251]
    MDA-MB-468 GI50
    14.12 μM
    Compound: 1, ATRA
    Growth inhibition of human MDA-MB-468 cells by MTT assay
    Growth inhibition of human MDA-MB-468 cells by MTT assay
    		[PMID: 25634130]
    MIA PaCa-2 IC50
    9.5 μM
    Compound: ATRA
    Concentration required to inhibit the colony formation of pancreatic human (PACA) cell lines by 50%
    Concentration required to inhibit the colony formation of pancreatic human (PACA) cell lines by 50%
    		[PMID: 10956204]
    MOLM-13 CC50
    1.24 μM
    Compound: ATRA; RA
    Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell growth measured after 96 hrs by WST-8 assay
    Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell growth measured after 96 hrs by WST-8 assay
    		[PMID: 33895500]
    NB-4 CC50
    1.5 μM
    Compound: ATRA; RA
    Antiproliferative activity against human NB-4 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
    Antiproliferative activity against human NB-4 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
    		[PMID: 33895500]
    PC-3 GI50
    12.64 μM
    Compound: ATRA, Tretinoin
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 25701251]
    PC-3 CC50
    12.7 μM
    Compound: ATRA; RA
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay
    		[PMID: 33895500]
    PC-3 IC50
    2 μM
    Compound: 1
    Growth inhibition of human PC3 cells after 6 days by MTT assay
    Growth inhibition of human PC3 cells after 6 days by MTT assay
    		[PMID: 15615521]
    PC-3 GI50
    36.3 μM
    Compound: 1, ATRA
    Growth inhibition of human PC3 cells by MTT assay
    Growth inhibition of human PC3 cells by MTT assay
    		[PMID: 25634130]
    PC-3 GI50
    7.6 μM
    Compound: ATRA
    Growth inhibition of human PC3 cells after 5 days by MTT assay
    Growth inhibition of human PC3 cells after 5 days by MTT assay
    		[PMID: 18543902]
    Raji IC50
    15.4 nM
    Compound: retinoic acid
    Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells after 48 hrs
    Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells after 48 hrs
    		[PMID: 17503850]
    SK-BR-3 GI50
    22.9 μM
    Compound: 1, ATRA
    Growth inhibition of human SKBR3 cells by MTT assay
    Growth inhibition of human SKBR3 cells by MTT assay
    		[PMID: 25634130]
    T47D IC50
    0.006 μM
    Compound: 1
    Growth inhibition of human T47D cells after 6 days by MTT assay
    Growth inhibition of human T47D cells after 6 days by MTT assay
    		[PMID: 15615521]
    T47D GI50
    0.82 μM
    Compound: ATRA, Tretinoin
    Cytotoxicity against human T47D cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human T47D cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 25701251]
    體外研究
    (In Vitro)

    維甲酸（全反式維甲酸，ATRA）是維生素 A 的一種高效衍生物，幾乎所有必需的生理過程和功能都需要維甲酸，因為它參與超過 530 種不同基因的轉(zhuǎn)錄調(diào)節(jié)。視黃酸通過作為核視黃酸受體 (RARα-γ) 的激活配體發(fā)揮其作用，核視黃酸受體與視黃酸 X 受體 (RXRα-γ) 形成異二聚體[1]。
    視黃酸 (RA) 以低親和力與 PPARα 和 PPARγ 結(jié)合，Kd 值為 100-200 nM。 相比之下，視黃酸與 PPARβ/δ 結(jié)合的 Kd 為 17 nM，顯示出高親和力和同種型選擇性[2]。
    未分化的 P19 細(xì)胞表達(dá)視黃酸 (RA) 受體 RARα、RARβ、RARγ 和 PPARβ/δ，以及視黃酸結(jié)合蛋白 CRABP-II 和 FABP5。 通過用視黃酸處理細(xì)胞誘導(dǎo)分化導(dǎo)致 CRABP-II 的瞬時上調(diào)和 FABP5 的下調(diào)，這在各自的蛋白質(zhì)和 mRNA 水平上觀察到。
    在最初的下降之后，與未分化的 P19 細(xì)胞相比，成熟神經(jīng)元中 FABP5 蛋白和 mRNA 的水平增加了 2-2.5 倍。 誘導(dǎo)分化不會顯著影響 RARα 或 PPARβ/δ 的水平。 到第 4 天，RARγ mRNA 的水平降低了約 5 倍，并且在成熟神經(jīng)元中保持較低水平[3]。
    視黃酸 (RA) 是一種來源于視黃醇（維生素 A）的形態(tài)發(fā)生素，在細(xì)胞生長、分化和器官發(fā)生中起重要作用。 視黃酸與視黃酸受體 (RAR) 和視黃酸 X 受體 (RXR) 相互作用，進而調(diào)控靶基因的表達(dá)[4]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    分子量

    300.44

    Formula

    C20H28O2
    CAS 號
    性狀

    固體

    顏色

    Light yellow to yellow

    中文名稱

    視黃酸；維生素A酸；維甲酸
    結(jié)構(gòu)分類
    初始來源
    運輸條件

    Room temperature in continental US; may vary elsewhere.
    儲存方式

    -20°C, sealed storage, away from moisture and light

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

    溶解性數(shù)據(jù)
    細(xì)胞實驗： 

    DMSO 中的溶解度 : 50 mg/mL (166.42 mM; 超聲助溶 (<60°C); 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

    配制儲備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 3.3285 mL 16.6423 mL 33.2845 mL
    5 mM 0.6657 mL 3.3285 mL 6.6569 mL
    查看完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C儲存時，請在6個月內(nèi)使用，-20°C儲存時，請在1個月內(nèi)使用。

    • 摩爾計算器

    • 稀釋計算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實驗：

    請根據(jù)您的 實驗動物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
    ——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: 2.5 mg/mL (8.32 mM); 懸濁液; 超聲加熱助溶

      此方案可獲得 2.5 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。

      以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (8.32 mM); 懸濁液

      此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的均勻懸濁液，懸濁液可用于口服和腹腔注射。

      以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

      2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。

    以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

    • 方案 一

      請依序添加每種溶劑： 50% PEG300    50% PBS

      Solubility: 5 mg/mL (16.64 mM); 懸濁液; Need ultrasonic and warming and heat to 40°C

    動物溶解方案計算器
    請輸入動物實驗的基本信息：

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數(shù)量

    只
    由于實驗過程有損耗，建議您多配一只動物的量
    請輸入您的動物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
    計算結(jié)果
    工作液所需濃度 : mg/mL
    儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

    您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
    動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請謹(jǐn)慎選擇該方案。
    請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.81%

    參考文獻
    Cell Assay
    [3]

    P19 cell are induced to undergo neuronal differentiation according to established procedures. Briefly, cells are cultured on 1% agarose-coated 10 cm dishes at 3×10 5 cells/mL in α-minimal essential medium supplemented with 10% FBS. Differentiation is induced by addition of Retinoic acid (1 μM) and medium containing Retinoic acid replaced 2 days later. On day 4, cell aggregates are collected by centrifugation, separated to single cells by trypsin/EDTA treatment, replated onto poly-L-lysine-coated plates, and cultured in α-minimal essential medium supplemented with 10% FBS. On day 6, medium is replaced with neurobasal medium containing B27 supplement and 2 mM GlutaMAX. Medium is replaced every 2 days for an additional week[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    參考文獻

    完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C儲存時，請在6個月內(nèi)使用，-20°C儲存時，請在1個月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.3285 mL 16.6423 mL 33.2845 mL 83.2113 mL
    5 mM 0.6657 mL 3.3285 mL 6.6569 mL 16.6423 mL
    10 mM 0.3328 mL 1.6642 mL 3.3285 mL 8.3211 mL
    15 mM 0.2219 mL 1.1095 mL 2.2190 mL 5.5474 mL
    20 mM 0.1664 mL 0.8321 mL 1.6642 mL 4.1606 mL
    25 mM 0.1331 mL 0.6657 mL 1.3314 mL 3.3285 mL
    30 mM 0.1109 mL 0.5547 mL 1.1095 mL 2.7737 mL
    40 mM 0.0832 mL 0.4161 mL 0.8321 mL 2.0803 mL
    50 mM 0.0666 mL 0.3328 mL 0.6657 mL 1.6642 mL
    60 mM 0.0555 mL 0.2774 mL 0.5547 mL 1.3869 mL
    80 mM 0.0416 mL 0.2080 mL 0.4161 mL 1.0401 mL
    100 mM 0.0333 mL 0.1664 mL 0.3328 mL 0.8321 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Retinoic acid
    目錄號：
    HY-14649
    需求量：